294 related articles for article (PubMed ID: 26112923)
1. Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.
Urbanska K; Stashwick C; Poussin M; Powell DJ
Cancer Immunol Res; 2015 Oct; 3(10):1130-7. PubMed ID: 26112923
[TBL] [Abstract][Full Text] [Related]
2. Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
Perales-Puchalt A; Svoronos N; Rutkowski MR; Allegrezza MJ; Tesone AJ; Payne KK; Wickramasinghe J; Nguyen JM; O'Brien SW; Gumireddy K; Huang Q; Cadungog MG; Connolly DC; Tchou J; Curiel TJ; Conejo-Garcia JR
Clin Cancer Res; 2017 Jan; 23(2):441-453. PubMed ID: 27435394
[TBL] [Abstract][Full Text] [Related]
3. Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells.
Wang C; Hu W; Shen L; Dou R; Zhao S; Shan D; Yu K; Huang R; Li H
J Immunother; 2014 Sep; 37(7):351-9. PubMed ID: 25075564
[TBL] [Abstract][Full Text] [Related]
4. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
5. Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.
Perales-Puchalt A; Wojtak K; Duperret EK; Yang X; Slager AM; Yan J; Muthumani K; Montaner LJ; Weiner DB
Mol Ther; 2019 Feb; 27(2):314-325. PubMed ID: 30554854
[TBL] [Abstract][Full Text] [Related]
6. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
7. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
10. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
11. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
12. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
13. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
[TBL] [Abstract][Full Text] [Related]
14. Dual-specific T cells combine proliferation and antitumor activity.
Kershaw MH; Westwood JA; Hwu P
Nat Biotechnol; 2002 Dec; 20(12):1221-7. PubMed ID: 12415288
[TBL] [Abstract][Full Text] [Related]
15. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
[TBL] [Abstract][Full Text] [Related]
16. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
17. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
18. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
19. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
[TBL] [Abstract][Full Text] [Related]
20. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]